188 related articles for article (PubMed ID: 37605122)
1. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases.
Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T
BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122
[TBL] [Abstract][Full Text] [Related]
2. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
[TBL] [Abstract][Full Text] [Related]
3. TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III
Boku S; Satake H; Ohta T; Mitani S; Kawakami K; Suzuki Y; Matsumoto T; Terazawa T; Yamazaki E; Hasegawa H; Ikoma T; Uemura M; Yamaguchi T; Naito A; Ishizuka Y; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Tsujinaka T; Kato T; Satoh T; Kagawa Y
Future Oncol; 2022 Dec; 18(38):4153-4160. PubMed ID: 36475784
[TBL] [Abstract][Full Text] [Related]
4. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated
Van Cutsem E; Taieb J; Yaeger R; Yoshino T; Grothey A; Maiello E; Elez E; Dekervel J; Ross P; Ruiz-Casado A; Graham J; Kato T; Ruffinelli JC; André T; Carrière Roussel E; Klauck I; Groc M; Vedovato JC; Tabernero J
J Clin Oncol; 2023 May; 41(14):2628-2637. PubMed ID: 36763936
[TBL] [Abstract][Full Text] [Related]
5. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
6. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
7. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T
ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068
[TBL] [Abstract][Full Text] [Related]
8. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J
ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981
[TBL] [Abstract][Full Text] [Related]
9. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
11. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
[TBL] [Abstract][Full Text] [Related]
12. The BEETS (JACCRO CC-18) trial: an observational and translational study of
Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
[TBL] [Abstract][Full Text] [Related]
13. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Li S; Hu H; Ding D; Zhu Y; Huang J
Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
[TBL] [Abstract][Full Text] [Related]
15. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
[TBL] [Abstract][Full Text] [Related]
16. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study.
Sakata H; Murase M; Kato T; Yamaguchi K; Sugihara K; Suzuki S; Yoshino T
Int J Clin Oncol; 2023 Jan; 28(1):139-144. PubMed ID: 36355316
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF
Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T
Clin Colorectal Cancer; 2024 Mar; ():. PubMed ID: 38553360
[TBL] [Abstract][Full Text] [Related]
18. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
19. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
[TBL] [Abstract][Full Text] [Related]
20. [BRAF V600E-mutant colorectal cancers: Where are we?].
Lièvre A; de la Fouchardière C; Samalin E; Benoist S; Phelip JM; André T; Lledo G
Bull Cancer; 2020 Sep; 107(9):881-895. PubMed ID: 32674932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
